Supplementary Digital Content

Table 1:Updated and original tests: Percentage of subjects with hSBA-MenCtiters≥ 1:4 and ≥1:8 and GMTs (ATP cohort for persistence Year 1, subset of subjects retested with updated hSBA-MenC test)

|  | **≥ 1:4** | **≥ 1:8** | **GMT** |
| --- | --- | --- | --- |
|  |  | **95% CI** |  | **95% CI** |  | **95% CI** |
| **Antibody** | **Group** | **Timing** | **N** | **n** | **%** | **LL** | **UL** | **n** | **%** | **LL** | **UL** | **value** | **LL** | **UL** |
| **Updated test** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| hSBA-MenC  | HibMenCY x 4 | Year 1 | 23 | 23 | 100 | 85.2 | 100 | 23 | 100 | 85.2 | 100 | 186.4 | 106.5 | 326.2 |
| (updated) | Hib | Year 1 | 9 | 2 | 22.2 | 2.8 | 60.0 | 1 | 11.1 | 0.3 | 48.2 | 2.9 | 1.6 | 5.3 |
|  | HibMenCY x 1 | Year 1 | 10 | 6 | 60.0 | 26.2 | 87.8 | 6 | 60.0 | 26.2 | 87.8 | 13.6 | 3.4 | 54.6 |
| **Original test**  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| hSBA-MenC  | HibMenCY x 4 | Year 1 | 23 | 23 | 100 | 85.2 | 100 | 23 | 100 | 85.2 | 100 | 247.7 | 155.5 | 394.5 |
| (original) | Hib | Year 1 | 9 | 3 | 33.3 | 7.5 | 70.1 | 3 | 33.3 | 7.5 | 70.1 | 5.5 | 1.7 | 17.5 |
|  | HibMenCY x 1 | Year 1 | 10 | 7 | 70.0 | 34.8 | 93.3 | 7 | 70.0 | 34.8 | 93.3 | 27.4 | 6.6 | 114.0 |

GMT = geometric mean antibody titre calculated on all subjects

N = number of subjects with available results

n/% = number/percentage of subjects with titre equal to or above specified value

95% CI = 95% confidence interval; LL = Lower Limit, UL = Upper Limit

Year 1 = 309-421 days post- dose 4 blood sample